Project Grant R01AI193067
- Federal Project Grant Award Summary Louisiana State University received a $392,409 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2030. The award supports research investigating immune manipulation mechanisms in Staphylococcus aureus colonization and infection, with particular focus on developing potential therapeutic interventions against...
- Federal Grant Award Summary Louisiana State University Health Sciences Center-Shreveport received a $660,723 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 16, 2026, with a completion date of March 31, 2031. The grant funds investigator-initiated biomedical research examining the role of Z-form nucleic acid binding protein 1 (ZBP1) in controlling Herpes Simplex Virus Type...
- Federal Grant Award Summary Louisiana State University Health Sciences Center New Orleans received a $700,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 5, 2025, with completion scheduled for August 31, 2027. The grant supports fundamental biomedical research investigating the role of neutrophils in cystic fibrosis (CF) pathogenesis. This research addresses...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Illinois a $440,908 Project Grant on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop innovative therapeutic approaches targeting methicillin-resistant Staphylococcus aureus (MRSA). The project, concluding January 31, 2028, focuses on engineering artificial vesicles (AVs) inspired by natural extracellular vesicles to...
- Federal Project Grant Award Summary Wayne State University received a $1,341,058 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 13, 2026, through January 31, 2031. The research initiative, titled "Translating Phage-Antibiotic Synergy to Combat Multi-Drug Resistant Staphylococcus aureus Infections," addresses the critical clinical challenge of treatment...
- Federal Grant Award Summary New York University School of Medicine received a $3.21 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 25, 2025, with a completion date of June 30, 2029. The award funds research into real-time detection of Staphylococcus aureus transmission in hospital settings, with particular emphasis on methicillin-resistant S. aureus (MRSA)....
- Federal Project Grant Award Summary The University of South Florida received a $470,953 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2030. This five-year research initiative will produce biomedical research and scientific knowledge concerning the role of SSR42, a regulatory RNA molecule, in virulence factor regulation and pathogenic...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Nebraska Medical Center (UNMC) a Project Grant of $586,920 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 15, 2026, with a completion date of May 31, 2031. This research grant funds an investigator-initiated biomedical study examining the role of pyruvate acquisition in Staphylococcus aureus survival within intracellular environments,...
- Federal Project Grant Award Summary The University of Notre Dame DU Lac received a $748,964 Project Grant award dated May 22, 2026, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research through April 30, 2031, focused on developing a novel class of boron-based small molecule inhibitors designed to abrogate antibiotic resistance in methicillin-resistant Staphylococcus aureus...
- Federal Grant Award Summary The University of South Florida received a $949,785 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 23, 2025, with completion targeted for June 30, 2030. This award supports fundamental biomedical research investigating the role and regulation of secreted proteases produced by Staphylococcus aureus. The research seeks to elucidate how...
Louisiana State University received a $599,480 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 10, 2026, with performance completion targeted for May 31, 2031. The grant funds basic biomedical research investigating the regulation of neutrophil endoplasmic reticulum stress response by inositol-requiring enzyme 1-alpha (IRE1A), with the ultimate objective of developing immunomodulatory strategies to enhance host defenses against drug-resistant bacterial pathogens, specifically methicillin-resistant Staphylococcus aureus (MRSA). The research deliverables include scientific investigations examining IRE1A's role in coordinating critical neutrophil signaling events, including calcium mobilization, histone citrullination, and mitochondrial reactive oxygen species production necessary for antimicrobial neutrophil extracellular trap (NET) formation. The project addresses the urgent public health challenge posed by MRSA infections, which carry a 14% mortality rate and impose an estimated $500 million annual healthcare burden in the United States, while developing innovative treatment approaches as alternatives to antibiotic-based interventions in the face of increasing vancomycin resistance. Research will be conducted at LSU's Baton Rouge, Louisiana facility.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $599.5k | 6/11/26 |